Using either drug as Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating and preventing seasonal and pandemic influenza.

The World Health Organization and the CDC-P have claimed that early treatment with oseltamivir (Tamiflu, Roche) can limit the spread of influenza and reduce the risk of lower respiratory complications due to the flu. Suffice it to say, he’s a smart guy and has been a major contributor in the evidence-based medicine movement in primary care.In any case, back to the question, does oseltamivir work?

Use of the neuraminidase inhibitor, oseltamivir (Tamiflu) appears to be preferred to use of zanamivir (Relenza), likely due to ease of use, but in December 2008 the CDC-P reported a high level of resistance of influenza A/H1N1 viruses to oseltamivir. This The latest updated Cochrane Review, published on 10 April 2014, is based on full internal reports of 20 Tamiflu and 26 Relenza trials.

2011—FOI request results in European Medicines Agency releasing 20 000 pages of oseltamivir data 2006—Cochrane review concludes that oseltamivir reduces complications and symptoms in seasonal flu.

These trials involved more than 24,000 people and the findings challenge the historical assumption that NIs are effective in combating influenza. Just tell the patient the contents of the prior paragraph and let them help decide. Immunocompromised patients were excluded. Prophylaxis with either zanamivir or oseltamivir was associated with an 8% absolute reduction in developing influenza after the introduction of a case into a household (RD-0.08, 95% CI-0.12 to -0.05, P < … A159 is an amalgamation of two long‐standing Cochrane reviews on the effects of NIs for influenza in healthy adults ... (PEP) and treatment of influenza. Exploring issues and controversies in the relationship between science and medicineDoes Tamiflu have any meaningful effects on the prevention or treatment of influenza? Why?

2009—The BMJ publishes critical Cochrane update review of oseltamivir. Not David Newman. Considering the drug’s been on the market for almost 15 years, and is widely used, you should expect this question has been answered after 15 flu seasons. The balance between benefits and harms should be considered when making decisions about use of both NIs for either the prophylaxis or treatment of influenza. And oseltamivir has been shown to be effective prophylaxis for influenza; not as effective as the typical annual vaccine – but then again, vaccines to new strains take months to develop and predicting next year’s predominant flu strains isn’t always perfect. Here we report on the part of our Cochrane review on oseltamivir for influenza in adults and children.

Moreover, the drug does not seem to prevent complications like hospitalizations. The authors suggest that preferential use of a single drug for the treatment of viral illnesses and/or sequential use of antiviral drugs (starting one drug after development of resistance to another) are potentially hazardous therapeutic strategies that increase the likelihood of resistance.

If the providers were not going to do the tests and give the antibiotics in the first place then flu tests seem to be a waste of time and money (their sensitivity is generally low – about 70% – but specificity is high). Take this short survey so Cochrane can better meet your needs in the future.

They believe that it is time to consider a more rational approach that would include increased immunization against influenza, point-of-care testing and development of algorithms that would target for treatment those patients at the greatest risk for life- threatening complications. The author calls for organized efforts to ensure accountability on the part of the pharmaceutical industry.

However, the data are more nuanced than the investigators themselves believe.